168,905 Shares in Genmab A/S (NASDAQ:GMAB) Bought by AIMZ Investment Advisors LLC

AIMZ Investment Advisors LLC acquired a new position in Genmab A/S (NASDAQ:GMAB) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 168,905 shares of the company’s stock, valued at approximately $3,525,000. Genmab A/S comprises 1.2% of AIMZ Investment Advisors LLC’s holdings, making the stock its 26th largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after purchasing an additional 827 shares during the period. GAMMA Investing LLC increased its stake in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares in the last quarter. Eagle Asset Management Inc. raised its holdings in shares of Genmab A/S by 10.0% during the third quarter. Eagle Asset Management Inc. now owns 12,356 shares of the company’s stock worth $285,000 after acquiring an additional 1,121 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Genmab A/S by 43.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after acquiring an additional 1,413 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Genmab A/S by 33.4% during the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock worth $120,000 after purchasing an additional 1,442 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Stock Up 0.5 %

GMAB stock opened at $22.73 on Friday. The firm has a market cap of $15.04 billion, a PE ratio of 13.06, a P/E/G ratio of 2.65 and a beta of 0.96. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88. The business has a 50 day moving average of $20.93 and a 200-day moving average of $22.83.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, research analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. BMO Capital Markets restated an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.